CTOs on the Move

Bioverativ

www.bioverativ.com

 
Bioverativ Inc. is an American multinational biotechnology that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia.
  • Number of Employees: 250-1000
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

InMed Diagnostics

InMed Diagnostics is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trellis Bioscience

Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.

ImmunoPrecise Antibodies

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.

Areteia Therapeutics

Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners` development unit, Validae Health.

Merck KGAA

Merck KGAA is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.